|
|
Merknamen in verschillende landen |
|
|
Handelsnamen zijn slechts een indicatie; de samenstelling van hulpstoffen kan per land variëren afhankelijk van de fabrikant
|
|
Accofil |
België, Duitsland, Groot Britannië, Kroatië |
|
Duperan |
Chili |
|
Filgen |
Argentinië, Chili |
|
Foltran |
Chili |
|
Granulokine |
Brazilië, Griekenland, Italië |
|
Hebervital |
Colombia |
|
Inmunef |
Colombia, Mexico |
|
Leucosos |
Colombia |
|
Lioplim |
Chili |
|
Neupogen |
Australië, België, Canada, Chili, Colombia, Denemarken, Duitsland, Ecuador, Egypte, Finland, Frankrijk, Groot Britannië, Ierland, Iran, Luxemburg, Maleisië, Marokko, Mexico, Nederland, nieuw Zeeland, Noorwegen, Oostenrijk, Polen, Portugal, Saudi-Arabië, Slovenië, Spanje, Turkije, USA, Venezuela, Verenigde Arabische Emiraten, Zweden, Zwitserland |
|
Neutromax |
Argentinië |
|
Neutropine |
Argentinië |
|
Nivestim |
België, Duitsland, Frankrijk, Groot Britannië, Nederland, Noorwegen |
|
Ratiograstim |
Duitsland, Groot Britannië, Oostenrijk, Zweden |
|
Tevagrastim |
België, Brazilië, Chili, Duitsland, Groot Britannië, Kroatië, Nederland, Noorwegen, Spanje, Zweden, Zwitserland |
|
|
|
|
Literatuur : Filgrastim |
|
|
type |
publicatie |
| 99 |
Artikel |
Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090. |
| 104 |
Artikel |
Hall PD, Yui D, Lyons S, Bosso JA. Compatibility of filgrastim with selected antimicrobial drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 185-189. |
| 182 |
Artikel |
Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60. |
| 244 |
Artikel |
Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913. |
| 2269 |
Artikel |
Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551. |
| 3128 |
fabrikant |
Mitomycine (Amétycine®) - Résumé Caractéristiques du Produit Prostrakan 2013 |
| 3249 |
Artikel |
Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169. |
| 3256 |
Artikel |
Burnett B, Radic I. Stability of Hospira filgrastim following changes to thermal and photic storage conditions. EJHP 2011 ; 17, 5: 49-56. |
| 3474 |
fabrikant |
Fluorouracil - Summary of Product Characteristics Accord Healthcare Limited 2009 |
| 3618 |
fabrikant |
Filgrastim (Neupogen®) - Summary of Product Characteristics Amgen 2014 |
| 3828 |
Poster |
Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015 |
| 3829 |
Poster |
So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015 |
| 4055 |
Artikel |
Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44 |
| 4380 |
fabrikant |
Posaconazole (Noxafil®) - Summary of Product Characteristics Merck Sharp & Dohme Limited 2019 |
| 4471 |
fabrikant |
Amétycine 10 mg poudre pour solution injectable - Résumé des caractéristiques du produit - Oct 10, 2019 Kyowa Kirin Pharma 2019 |
| 4521 |
Artikel |
Polo C, D’Huart E, Lesperlette G, Vigneron J, Meyer F, Demoré B. Compatibility of injectable posaconazole with drugs commonly used in a hematology care unit. Pharmaceutical Technology in Hospital Pharmacy 2020 |
| 4650 |
fabrikant |
Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021. Advanz Pharma 2021 |
|
|